Chemocentryx, Inc.

Bristol-Myers Squibb Compnay

J J Kim Wright

Subhabrata Bapi Sen

James Bradley Aggen

Andrew M K Pennell

Daniel J Dairaghi

Penglie Zhang

Wei Yu Chen

Brian E McMaster

Nicholas A Meanwell

John F Kadow

Kap-Sun Yeung

Thomas Stephen Coulter

Valeri Martichonok

Malcolm Taylor

David Johnston

Michelle E Farkas

Wei Chen

Subharata Sen

Daniel Joseph Dairaghi

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

Substituted piperazines

This invention provides compounds of Formula I, including pharmaceutically acceptable salts thereof, having drug and bio-affecting properties, their pharmaceutical compositions and method of use. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS. The compounds of Formula I have the formula wherein:   

Indole, azaindole and related heterocyclic N-substituted piperazine derivatives

Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2- and/or CCR3-mediated diseases, and as controls in assays for the identification of competitive receptor antagonists for the above chemokine receptors.

Bicyclic and bridged nitrogen heterocycles

Growing community of inventors

Redwood City, CA, United States of America

J J Kim Wright